This document provides an introduction to Indian pharmacopoeias and their history and development. It discusses that the Indian Pharmacopoeia is the official book that contains standards for drugs and related substances in India. It must be complied with by manufacturers. The document outlines the various editions of the Indian Pharmacopoeia published since 1955 and describes the typical contents and structure of monographs in the publications. It also provides a brief introduction to the National Formulary of India and its editions.
Pharmacopoeia: the word derives from the ancient Greek word pharmakon means drug & poeia- to make.
It is a legally binding collection, prepared by a national or regional authority& contains list of medicinal substances, crude drug & formulas for making preparation from them.
This presentation provide you the basic knowledge about the Pharmacopoeia and later about the Indian Pharmacopoeia. Details about the Indian Pharmacopoeia i.e Who publish it? When first edition was published? Published Addendum? Latest edition and its Addendum?
In ancient India the sources of drugs were of vegetable, animal and mineral origin.(Ayurveda).They were prepared empirically by few experienced persons. Knowledge of that medical system was usually kept secret within a family (Folkore).There were no scientific methods of standardization of drugs.
Historical background and development of profession of pharmacy: History of profession of Pharmacy in India in relation to pharmacy education, industry and organization, Pharmacy as a career, Pharmacopoeias: Introduction to IP, BP, USP and Extra Pharmacopoeia.
HISTORICAL BACKGROUND & DEVELOPMENT OF PROFESSION OF PHARMACYTeny Thomas
The following presentation deals with what the course of pharmacy is and what a pharmacist is. Also a short brief on the historical growth of the profession of pharmacy when related to education and industry is also discussed here. A detailed view on career in pharmacy is described lastly.
Pharmacopoeia: the word derives from the ancient Greek word pharmakon means drug & poeia- to make.
It is a legally binding collection, prepared by a national or regional authority& contains list of medicinal substances, crude drug & formulas for making preparation from them.
This presentation provide you the basic knowledge about the Pharmacopoeia and later about the Indian Pharmacopoeia. Details about the Indian Pharmacopoeia i.e Who publish it? When first edition was published? Published Addendum? Latest edition and its Addendum?
In ancient India the sources of drugs were of vegetable, animal and mineral origin.(Ayurveda).They were prepared empirically by few experienced persons. Knowledge of that medical system was usually kept secret within a family (Folkore).There were no scientific methods of standardization of drugs.
Historical background and development of profession of pharmacy: History of profession of Pharmacy in India in relation to pharmacy education, industry and organization, Pharmacy as a career, Pharmacopoeias: Introduction to IP, BP, USP and Extra Pharmacopoeia.
HISTORICAL BACKGROUND & DEVELOPMENT OF PROFESSION OF PHARMACYTeny Thomas
The following presentation deals with what the course of pharmacy is and what a pharmacist is. Also a short brief on the historical growth of the profession of pharmacy when related to education and industry is also discussed here. A detailed view on career in pharmacy is described lastly.
Introduction to Social Pharmacy, Definition, Social Pharmacy as a Discipline, Scope of Social Pharmacy in Improving Public Health, Role of Pharmacist in Public Health, Concept of Health, Dimensions of Health, Determinants of Health, Health Indicators.
it is GTU based syllabus chapter and all the points are covered like... handling of prescription , etc... very helpful for pharmacy students...and its in easy language..
Introduction to Social Pharmacy, Definition, Social Pharmacy as a Discipline, Scope of Social Pharmacy in Improving Public Health, Role of Pharmacist in Public Health, Concept of Health, Dimensions of Health, Determinants of Health, Health Indicators.
it is GTU based syllabus chapter and all the points are covered like... handling of prescription , etc... very helpful for pharmacy students...and its in easy language..
Pharmacopoeias,Sources of Impurities in Medicinal agents and Limit testssaimuniswetha1
Today's Topic Pharmacopoeias, Sources of Impurities in Medicinal agents and Limit tests for Chlorides, Sulphates, Heavy Metals, Lead, Iron in Pharmaceutical Analysis subject for B.pharmacy 1st year as per JNTUA Syllabus...
Introduction of Inorganic Chemistry, History of Pharmacopoeia.pptxMs. Pooja Bhandare
Introduction of Inorganic Chemistry, History of Pharmacopoeia, Pharmaceutical Chemistry, Inorganic Chemistry:
IMPORTANTS OF INORGANIC CHEMISTRY, Introduction of Pharmacopoeia, Types of Pharmacopoeia, History of pharmacopoeia, HISTROY OF INDIAN PHARMACOPOEIA
Content of pharmacopoeia Introduction including general Notices
Monographs of the official drugs
Appendices
Monographs of herbal drugs: General parameters of
monographs of herbal drugs and comparative study in IP, USP,
Ayurvedic Pharmacopoeia, Siddha and Unani Pharmacopoeia,
American herbal pharmacopoeia, British herbal pharmacopoeia,
WHO guidelines in quality assessment of herbal drugs.
Description about what is pharmacopoeia? different pharmacopoeia and there edition. What is monograph and there comparative studies in different pharmacopoeias along with monograph format in per different pharmacopoies.
For B Pharmacy Students
Subscribe to the YouYube Channel #Professor_Beubenz
https://www.youtube.com/channel/UC84jGf2iRN5VjwnQqi6qmXg?view_as=subscriber
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
1. INTRODUCTION TO INDIAN
PHARMACOPOEIAS
Mr. Ajay Kumar Dubey, Assistant Professor, Institute of Pharmacy
Subject- Inorganic Pharmaceutical Chemistry (BP104T)
Email- a84dubey@gmail.com
Dr. Manju Pandey, Director, Institute of Pharmacy
Email- director.pharma@srmu.ac.in
Shri Ramswaroop Memorial University, Barabanki-225003
2. Indian Pharmacopoeia
• Under the Drugs and Cosmetics Act 1940 , The Indian
Pharmacopoeia is an official book that contains the standards
for drugs and other related substances included in the
pharmacopoeia.
• The drugs and other related substances prepared by
pharmaceutical manufacturers must comply with these
standards .
• For the preparation of Pharmacopoeia of India, the
pharmacopoeias of other countries, like British, Europe,
United States, USSR, Japan, the National Formulary (USA)
and Merck Index were consulted .
3. History of development of Indian Pharmacopoeia
• The government of India published the Indian pharmacopoeial
list in 1946, as a supplement to the British Pharmacopoeia.
• Indian Pharmacopoeial List contain list of drugs both included
and not included in the British Pharmacopoeia along with
standards to secure their usefulness, tests for identity and
purity.
• The Govt. of India constituted a permanent Indian
Pharmacopoeia Committee in 1948 .
• This committee was assigned the task of preparing Indian
Pharmacopoeia and to keep it up-to-date.
4. Editions of Indian Pharmacopoeia Indian Pharmacopoeia
• 1955 - First edition , followed by supplement in 1960
• Indian Pharmacopoeia 1966 - Second edition , followed by supplement in
1975
• Indian Pharmacopoeia 1985 - Third edition , followed by its addendum in
1989 and 1991
• Indian Pharmacopoeia 1996 - Fourth edition , followed by its addendum
2000, supplement 2000 for Veterinary Products, addendum 2002 and
addendum 2005
• Indian Pharmacopoeia 2007 - Fifth edition , followed by addendum 2008
• Indian Pharmacopoeia 2010 - Six edition , followed by its addendum 2012
• Indian Pharmacopoeia 2014 with DVD - Seventh edition
• Indian Pharmacopoeia 2018 with DVD - Eighth edition
5. Number of volumes in each edition of IP
• IP 1955, 1965 and 1985 was published in 1
volumes
• IP 1996 was published in 2 volumes
• IP 2007 and 2010 was published in 3 volumes
• IP 2014 was published in 4 volumes
• IP 2018 was published in 4 volumes
6. Contents of the IP 2014 Volume-1
• Introduction General Chapters
• General Notices
• Test Methods
• Apparatus
• Biological Methods
• Chemical Methods
• Physical and Physicochemical Methods
• Pharmaceutical Methods
• Tests on Herbal Products
• Tests on Vaccines
• Tests on Blood and Blood Blood-related Products
• Reference Data
• Reagents and Solutions
• General Tests
• Containers
• Tables
7. Contents of the IP 2014 Volume-2
• General Notices General Monographs on
Dosage Forms Monographs on Drug
substances, Dosage forms and Pharmaceutical
Aids
• Monographs A to M
8. Contents of the IP 2014 Volume-3
• General Notices
• Monographs on Drug substances,
• Dosage forms and Pharmaceutical aids
• Monographs N to Z
• Monographs on Vaccines and Immunosera for
Human Use
• Monographs on Herbs and Herbal Products
• Monographs on Blood and Blood Blood related
Products
• Monographs on Biotechnology Products
9. Contents of the IP 2014 Volume-4
• Monographs on Veterinary Products o
• Non Non-Biological
• Biological
• Diagnostics Index
10. MONOGRAPH
Title of the Monograph : The main name of the substance (The
International Non-proprietary Name (INN) approved by the World
Health Organization (WHO )).
Subsidiary or abbreviated title or synonym : The common name(s), if
any, of the substance.
Chemical formula and Molecular Weight of the substance : If
necessary, its I.U.P.A.C. chemical name and/or its chemical structure
is also given .
Standards: Prescribes the standards of purity and strength e.g. Sodium
bicarbonate IP contains not less than 99.0 % and not more than
100.5 % of NaHCO3.
Description : A brief description of the physical form of the material,
including colour, texture, whether hygroscopic, odour, if readily
apparent, and any other characteristic
11. MONOGRAPH
Solubility :
Identification : At least two or three identification tests, starting with
physical and instrumental tests and ending with general chemical
reactions is given.
Tests of purity: These tests include melting point, boiling point, weight
per ml, limit tests for chloride, sulfates , iron, heavy metals, lead and
arsenic, specific optical rotation, sulfated ash, loss on drying, pH of
solution, etc. as may be applicable for the substance.
Method of Assay: The term ‘Assay’ is used in pharmacopoeias for
quantitative determination of principal ingredients of the official
substances and of their preparations.
Storage : Prescribes some conditions for the storage of some official
substances which are likely to deteriorate if not properly stored.
12. NATIONAL FORMULARY OF INDIA
• The National Formulary of India would prove to be the
authoritative guide to prescribing, dispensing and
administering medicines for all healthcare professionals.
The National Formulary of India editions are as follows: -
• National Formulary of India 1960 -The first edition of NFI
• National Formulary of India 1966 -The Second edition of NFI
• National Formulary of India 1979 –The Third edition of NFI
• National Formulary of India 2011- Fourth Edition It contains
information about drug interaction, resistance, cumulative
effects, drug dependence, prescription writing etc.
13. CONTENTS OF NATIONAL FORMULARY OF INDIA
• List of Medicines in NFI
• Common Abbreviations
• General Advice to Prescribers
• Alphabetical listing of different classes of drugs with Indications .
• Availability
• Dose .
• Contraindications
• Precautions
• Adverse effects
• Storage
• Appendices
• Index